David J. Einstein
Advanced in WT1-Related Wilms Tumor Syndromes

Dr. David J. Einstein

Internal Medicine | Oncology
Beth Israel Deaconess Medical Center
Beth Israel Deaconess Medical Center - Hematology/Oncology
330 Brookline Avenue, Shapiro 9, 
Boston, MA 
On Staff At
Offers Telehealth

Advanced in WT1-Related Wilms Tumor Syndromes
Beth Israel Deaconess Medical Center
Beth Israel Deaconess Medical Center - Hematology/Oncology
330 Brookline Avenue, Shapiro 9, 
Boston, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

David Einstein is an Internal Medicine specialist and an Oncologist in Boston, Massachusetts. Dr. Einstein is rated as an Advanced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Prostate Cancer, Renal Cell Carcinoma (RCC), Familial Prostate Cancer, Upper Tract Urothelial Carcinoma (UTUC), and Prostatectomy.

His clinical research consists of co-authoring 61 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Tufts University School Of Medicine
Residency
Tufts Medical Center
Specialties
Internal Medicine
Oncology
Licenses
Internal Medicine in MA
Board Certifications
American Board Of Internal Medicine
Fellowships
Beth Israel Deaconess Medical Center
Hospital Affiliations
Beth Israel Deaconess Hospital - Needham
Beth Israel Deaconess Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Senior Whole Health
  • MEDICARE-MEDICAID PLAN
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

Beth Israel Deaconess Medical Center - Hematology/Oncology
330 Brookline Avenue, Shapiro 9, Boston, MA 02215
Call: 617-667-2100

Additional Areas of Focus

Dr. Einstein has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Bladder Cancer

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


5 Clinical Trials

A Phase 2 Multicohort Study of Nivolumab in Combination With Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone Sensitive Prostate Cancer Patients With DNA Damage Repair Defects or Inflamed Tumors
A Phase 2 Multicohort Study of Nivolumab in Combination With Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone Sensitive Prostate Cancer Patients With DNA Damage Repair Defects or Inflamed Tumors
Enrollment Status: Active_not_recruiting
Publish Date: August 14, 2025
Intervention Type: Drug
Study Drugs: Androgen deprivation therapy, Nivolumab, Docetaxel
Study Phase: Phase 2
A Phase 2 Study of Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate Cancer
A Phase 2 Study of Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 14, 2025
Intervention Type: Drug
Study Drug: Nivolumab
Study Phase: Phase 2
CELLO-1: A Phase 1b/2 Open-Label Study Evaluating Tazemetostat in Combination With Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer
CELLO-1: A Phase 1b/2 Open-Label Study Evaluating Tazemetostat in Combination With Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer
Enrollment Status: Terminated
Publish Date: December 09, 2024
Intervention Type: Drug
Study Drugs: Tazemetostat, Abiraterone/prednisone, Enzalutamide
Study Phase: Phase 1/Phase 2
A Phase 1, Open-Label Study of the Safety, Tolerability and Preliminary Clinical Activity of Allogeneic Invariant Natural Killer T (iNKT) Cells (agenT-797) as a Single Agent and in Combination With Approved Immune Checkpoint Inhibitors in Patients With Relapsed/ Refractory Solid Tumors
A Phase 1, Open-Label Study of the Safety, Tolerability and Preliminary Clinical Activity of Allogeneic Invariant Natural Killer T (iNKT) Cells (agenT-797) as a Single Agent and in Combination With Approved Immune Checkpoint Inhibitors in Patients With Relapsed/ Refractory Solid Tumors
Enrollment Status: Completed
Publish Date: April 24, 2024
Intervention Type: Drug
Study Phase: Phase 1
Avelumab, Palbociclib and Axitinib in in Treatment Naive Metastatic Clear Cell Renal Cell Carcinoma.
Avelumab, Palbociclib and Axitinib in in Treatment Naive Metastatic Clear Cell Renal Cell Carcinoma.
Enrollment Status: Withdrawn
Publish Date: September 07, 2023
Intervention Type: Drug
Study Drugs: Axitinib, Palbociclib, Avelumab
Study Phase: Phase 2
View 4 Less Clinical Trials

61 Total Publications

National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations.
National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 23, 2025
View All 61 Publications
Similar Doctors
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Bradley A. Mcgregor
Oncology | Hematology Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Bradley A. Mcgregor
Oncology | Hematology Oncology

Dana-Farber Cancer Institute, Inc.

450 Brookline Ave, 
Boston, MA 
 (0.2 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Bradley Mcgregor is an Oncologist and a Hematologist Oncology provider in Boston, Massachusetts. Dr. Mcgregor is rated as an Elite provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Renal Cell Carcinoma (RCC), Urothelial Cancer, Muscle Invasive Bladder Cancer, Tissue Biopsy, and Nephrectomy. Dr. Mcgregor is currently accepting new patients.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Toni K. Choueiri
Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Toni K. Choueiri
Oncology

Dana-Farber Cancer Institute, Inc.

20 Prospect St, Suite 2, 
Milford, MA 
 (26.0 miles away)
508-473-1190
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Toni Choueiri is an Oncologist in Milford, Massachusetts. Dr. Choueiri is rated as an Elite provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, Urothelial Cancer, Nephrectomy, and Orchiectomy. Dr. Choueiri is currently accepting new patients.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Marc D. Michaelson
Oncology | Hematology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Marc D. Michaelson
Oncology | Hematology

The General Hospital Corporation

55 Fruit St, 
Boston, MA 
 (2.5 miles away)
617-726-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Marc Michaelson is an Oncologist and a Hematologist in Boston, Massachusetts. Dr. Michaelson is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Renal Cell Carcinoma (RCC), Prostate Cancer, Familial Prostate Cancer, Orchiectomy, and Nephrectomy. Dr. Michaelson is currently accepting new patients.

VIEW MORE WT1-RELATED WILMS TUMOR SYNDROMES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Einstein's expertise for a condition
ConditionClose
  • Elite
  • Prostate Cancer
    Dr. Einstein is
    Elite
    . Learn about Prostate Cancer.
    See more Prostate Cancer experts
  • Distinguished
  • Familial Prostate Cancer
    Dr. Einstein is
    Distinguished
    . Learn about Familial Prostate Cancer.
    See more Familial Prostate Cancer experts
  • Renal Cell Carcinoma (RCC)
    Dr. Einstein is
    Distinguished
    . Learn about Renal Cell Carcinoma (RCC).
    See more Renal Cell Carcinoma (RCC) experts
  • Upper Tract Urothelial Carcinoma (UTUC)
    Dr. Einstein is
    Distinguished
    . Learn about Upper Tract Urothelial Carcinoma (UTUC).
    See more Upper Tract Urothelial Carcinoma (UTUC) experts
  • Advanced
  • Bladder Cancer
    Dr. Einstein is
    Advanced
    . Learn about Bladder Cancer.
    See more Bladder Cancer experts
  • Chromophobe Renal Cell Carcinoma
    Dr. Einstein is
    Advanced
    . Learn about Chromophobe Renal Cell Carcinoma.
    See more Chromophobe Renal Cell Carcinoma experts
  • Clear Cell Sarcoma
    Dr. Einstein is
    Advanced
    . Learn about Clear Cell Sarcoma.
    See more Clear Cell Sarcoma experts
  • Familial Wilms Tumor 2
    Dr. Einstein is
    Advanced
    . Learn about Familial Wilms Tumor 2.
    See more Familial Wilms Tumor 2 experts
  • Muscle Invasive Bladder Cancer
    Dr. Einstein is
    Advanced
    . Learn about Muscle Invasive Bladder Cancer.
    See more Muscle Invasive Bladder Cancer experts
  • Prostatectomy
    Dr. Einstein is
    Advanced
    . Learn about Prostatectomy.
    See more Prostatectomy experts
View All 9 Advanced Conditions
  • Experienced
  • Adrenal Cancer
    Dr. Einstein is
    Experienced
    . Learn about Adrenal Cancer.
    See more Adrenal Cancer experts
  • Adrenocortical Carcinoma
    Dr. Einstein is
    Experienced
    . Learn about Adrenocortical Carcinoma.
    See more Adrenocortical Carcinoma experts
  • Adult Soft Tissue Sarcoma
    Dr. Einstein is
    Experienced
    . Learn about Adult Soft Tissue Sarcoma.
    See more Adult Soft Tissue Sarcoma experts
  • Choriocarcinoma
    Dr. Einstein is
    Experienced
    . Learn about Choriocarcinoma.
    See more Choriocarcinoma experts
  • Lymphofollicular Hyperplasia
    Dr. Einstein is
    Experienced
    . Learn about Lymphofollicular Hyperplasia.
    See more Lymphofollicular Hyperplasia experts
  • Non-Muscle Invasive Bladder Cancer
    Dr. Einstein is
    Experienced
    . Learn about Non-Muscle Invasive Bladder Cancer.
    See more Non-Muscle Invasive Bladder Cancer experts
View All 10 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved